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Background
We previously reported that combinations of DNA,
recombinant adenovirus serotype 5 (rAd5) and 35 (rAd35)
HIV-1 vaccines with clade A Env inserts elicit strong
T-cell responses. Here we investigate their ability to
induce cross-clade IgG binding antibody (bAb) responses.
Based on recent evidence that Ab to the V1V2 loop in Env
were correlated with reduced risk of HIV infection in the
RV144 efficacy trial, we also evaluated those responses.
Methods
HVTN 077 was a placebo-controlled, double-blinded trial
that randomized 192 healthy, HIV-uninfected, Ad35 neu-
tralizing antibody (nAb) seronegative participants into pla-
cebo (n=28) and 4 vaccine groups: rAd35/rAd5 (T1,
n=34), DNA/rAd5 (T2, n=48), and DNA/rAd35 (T3,
n=48) – in persons seronegative for Ad5 nAb; and DNA/
rAd35 (T4, n=34) seropositive for Ad5 nAb. Vaccines
were given at 0,6 months (T1) and 0,1,2, and 6 months
(T2-4). IgG bAb responses by multiplex assay against
Group M Consensus (Con S), clade A (00MSA 4076),
clade B (B.con.env03), and clade C (C.con.env03) gp140
and novel gp70 V1V2 scaffolds, V1V2 VRC A and V1V2
(Case A2), were measured 4 weeks post boost.
Results
High frequency responses were elicited against clade A
(T1 95.8%, T2 100%, T3 97.4%, T4 100%), clade B (T1
95.8%, T2 95.0%, T3 92.1%, T4 96.3%), clade C (T1 92%,
T2 76%, T3 76%, T4 78%), and Con S (T1-4 100%).
There were no significant between-group differences in
response frequency or magnitude. The majority also had
responses to V1V2 clade A (T1 100%, T2 87.8%,
T3 83.8%, T4 85.2%) and clade B (T1 58.3%, T2 65.9%,
T3 54.1%, T4 51.9%). The mean fluorescent intensity
was higher in T2 vs T1 (p=0.005) for clade A V1V2. No
significant differences were observed between other
groups.
Conclusion
All vaccine regimens tested elicited cross-clade bAb
responses, including those that target V1V2. rAd-based
HIV-1 vaccines, particularly using rare serotypes, warrant
further development.
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